Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
Autolus Therapeutics Plc
AUTL | US
1.33
USD0.01
0.76%
AUTL | US
About Autolus Therapeutics Plc
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
25/03/2026
Close
1.33
Open
1.35
High
1.37
Low
1.32
Autolus Therapeutics plc a clinical-stage biopharmaceutical company develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1) a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22 which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4 a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG a programmed T cell investigational therapy which is in preclinical trail targeting GD2 in development for the treatment of neuroblastoma; and AUTO8 a product candidate that is in a Phase I clinical trial for multiple myeloma. It also focuses on developing AUTO5 a preclinical TRBC2 programmed T cell product candidate for the treatment of peripheral T-cell lymphoma. The company was incorporated in 2014 and is headquartered in London the United Kingdom.
View LessAUTL | US
Risk
62.5
Sharpe
-0.33
Luna's Score
48/100
Recommendation
Hold
Luna says (AUTL | US)
What's Working
Strength based on increasing price with high volume
Value Stock (Price to Book < 3)
Strong Revenue Growth (> 10%)
What's not Working
Price Below SMA10D
High 6-Month Volatility (>65%)
Smallcap (300M - 2B USD)
High Market Beta (> 0.8)
Weak Operating Margin (< 10%)
Weak Sharpe Ratio (< 0.3)
Volatility Signals
Bearish: Increased Volatility (6-month > 1-month volatility)
Risk Meter
10 days
54.4%1 month
62.5%3 months
75.3%6 months
81.9%Returns
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
2.42
Debt to equity
0.55
Debt to assets
0.34
Ent. to EBITDA
0.03
Ent. to rev.
59.19
PEG
-
Other Fundamentals
EBITDA
-186.21M
MarketCap
353.91M
MarketCap(USD)
353.91M
Div. yield
-
Op. margin
-1.84K
Erngs. growth
-
Rev. growth
681.00
Ret. on equity
-61.80
Short ratio
14.14
Short perc.
5.12
Market Sentiment (SMA and Price signals)
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
SMAs: Stock Price Trends
Range10D
0.32
Range1M
0.62
Range3M
0.76
Volumes: Market Activity
Rel. volume
1.49
Price X volume
3.30M
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | 0.03 | - | Cheaper |
| Ent. to Revenue | 59.19 | - | Cheaper |
| PE Ratio | - | 41.03 | - |
| Price to Book | 2.42 | 15.55 | Cheaper |
| Dividend Yield | - | - | - |
| Std. Deviation (3M) | 75.34 | - | Par |
| Debt to Equity | 0.55 | -1.23 | Expensive |
| Debt to Assets | 0.34 | 0.25 | Expensive |
| Market Cap | 353.91M | - | Emerging |
